clofibrate has been researched along with etofibrate in 46 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 42 (91.30) | 18.7374 |
1990's | 3 (6.52) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (2.17) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Aragones, MD; Armijo, M; Catalán, RE; Martinez, AM; Priego, JG | 1 |
Catalan, RE; Maroto, ML; Piña, M; Priego, JG | 2 |
Gustafson, A | 1 |
Loewer, H; Mertz, DP; Suermann, I | 1 |
Pfeiffer, M; Tilsner, V | 1 |
Rahlfs, VW; Safer, A; Zimmermann, H | 1 |
Kłosiewicz-Latoszek, L; Szostak, WB | 1 |
Betz, E; Quack, G | 1 |
Basista, M; Bieroń, K; Czarnecka, H; Dembińska-Kieć, A; Grodzińska, L; Kedzior, A; Kostka-Trabka, E; Slawiński, M; Trabka, E; Zmuda, A | 1 |
Ojeda, G; Portolés, A; Portolés, MP; Rojo, JM | 1 |
Castro, M; Gómez-Coronado, D; Herrera, E; Lasunción, MA; Martín, A; Quack, G | 1 |
Palmer, RH | 1 |
Caslake, MJ; Cruickshank, A; Demant, T; Kilday, C; Packard, CJ; Series, JJ; Shepherd, J | 1 |
Armijo Castro, F; Gutierrez Fuentes, JA; Pire Solis, I; Vazquez Lopez, F | 1 |
Holm, E; Schatton, W | 1 |
Betz, E; Hämmerle, H | 1 |
Altmayer, P; Garrett, ER | 2 |
Chasseaud, LF; Schatton, W; Taylor, T; Waller, AR | 1 |
Bardosi, A; Goebel, HH; Scheidt, P | 1 |
Goebel, KM; Hausmann, L; Kaffarnik, H; Schneider, J; Schubotz, R; Zöfel, P | 1 |
Bochenek, W; Słowińska, R; Unlot, J | 1 |
Santafé Oroz, J; Segarra Domènech, J | 1 |
Díaz Méndez, M; Priego, JG | 1 |
Hoppe, HJ; Johnson, KI; Schatton, W | 1 |
Degenring, FH; Hotz, W; Schatton, W | 1 |
Schatton, W | 1 |
Kaffarnik, H; Schneider, J; Schubotz, R; Zöfel, P | 1 |
Lang, PD; Vollmar, J | 1 |
Djaja, S; Machalke, K; Richter, E | 1 |
Armijo, M; Ortega, MP; Priego, JG; Sunkel, C | 1 |
Altomonte, L; De Cunto, F; Greco, AV; Mingrone, G; Negrini, A | 1 |
Gardner, MR; Garrett, ER | 1 |
von Bock und Polach, U | 1 |
Udelhoven, P | 1 |
Ewert, M; Nachev, P; Oelschläger, H; Rothley, D | 1 |
Göhmann, E; Mertz, DP; Suermann, I | 1 |
Altomonte, L; Ghirlanda, G; Greco, AV; Manna, R; Mingrone, G; Pala, MA; Rebuzzi, A | 1 |
Steger, W | 1 |
Füsgen, I; Summa, JD | 1 |
Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W | 1 |
Mertz, DP | 1 |
2 review(s) available for clofibrate and etofibrate
Article | Year |
---|---|
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol | 1983 |
8 trial(s) available for clofibrate and etofibrate
Article | Year |
---|---|
[Etofibrate and clofibrate in double blind study].
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Nicotinic Acids; Placebos | 1976 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation | 1987 |
[Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Topics: Adult; Aged; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged | 1983 |
[Pharmacology and mechanism of action of etofibrate].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids | 1982 |
[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Theophylline; Xanthinol Niacinate | 1982 |
[Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged | 1981 |
[Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Hyperlipoproteinemias; Male; Middle Aged; Niacin; Nicotinic Acids; Triglycerides | 1980 |
[An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
Topics: Adolescent; Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Triglycerides | 1980 |
37 other study(ies) available for clofibrate and etofibrate
Article | Year |
---|---|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Effects of etofibrate, clofibrate and nicotinic acid on the cyclic AMP-protein kinase system in rats.
Topics: Adipose Tissue; Animals; Clofibrate; Clofibric Acid; Cyclic AMP; Cyclic GMP; In Vitro Techniques; Insulin; Liver; Male; Nicotinic Acids; Protein Binding; Protein Kinases; Rats | 1979 |
Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in normolipemic rats.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Lipid Metabolism; Lipids; Lipoproteins; Liver; Male; Nicotinic Acids; Phospholipids; Rats | 1979 |
Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in hyperlipidemic rats.
Topics: Animals; Clofibrate; Clofibric Acid; Diet; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Liver; Male; Nicotinic Acids; Rats; Triglycerides | 1979 |
Treatment of hyperlipoproteinemia type II with etofibrate.
Topics: Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Glucose Tolerance Test; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Liver Function Tests; Male; Middle Aged; Nicotinic Acids; Time Factors | 1979 |
[The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
Topics: Adult; Aged; Anticholesteremic Agents; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged | 1979 |
[Influence of etofibrate on plasmaviscosity in hyperlipoproteinemias (author's transl)].
Topics: Blood Viscosity; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Male; Middle Aged; Triglycerides | 1978 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol | 1991 |
[Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
Topics: Clofibrate; Clofibric Acid; Humans; Hypolipidemic Agents | 1990 |
Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis.
Topics: Animals; Arteriosclerosis; Clofibrate; Clofibric Acid; Disease Models, Animal; Hypolipidemic Agents; Rabbits | 1990 |
[Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
Topics: Adult; Arteriosclerosis Obliterans; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Male; Triglycerides | 1989 |
Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes.
Topics: Anaphylaxis; Animals; Antibody Formation; Antigen-Antibody Complex; Arteriosclerosis; Clofibrate; Clofibric Acid; Cyclic AMP; Cyclic GMP; Female; Hypersensitivity, Delayed; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Niacin; Thiophenes; Ticlopidine | 1985 |
Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.
Topics: Adipose Tissue; Animals; Clofibrate; Clofibric Acid; Fatty Acids, Nonesterified; Glycerol; Lipolysis; Lipoproteins, VLDL; Liver; Male; Palmitic Acid; Palmitic Acids; Rats; Rats, Inbred Strains; Triglycerides | 1988 |
Influence of etofibrate on low density lipoprotein metabolism.
Topics: Adult; Anticholesteremic Agents; Clofibrate; Clofibric Acid; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged | 1988 |
Concentration of clofibric acid in blood after the administration of delayed-release form of etofibrate.
Topics: Adult; Biotransformation; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Humans; Kinetics; Male; Tablets, Enteric-Coated | 1987 |
[Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Dietary Fats; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Triglycerides | 1986 |
Effect of etofibrate and its metabolites on atheromas of rabbits and on smooth muscle cell cultures.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Carotid Arteries; Cell Division; Cells, Cultured; Cholesterol; Cholesterol, Dietary; Clofibrate; Clofibric Acid; Clone Cells; Electric Stimulation; Fibroblasts; Lipoproteins, HDL; Male; Muscle, Smooth, Vascular; Rabbits; Triglycerides | 1986 |
Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
Topics: Animals; Clofibrate; Clofibric Acid; Dogs; Esters; Half-Life; Hypolipidemic Agents; Injections, Intravenous; Kinetics; Male; Niacin; Solubility; Solvents; Time Factors | 1985 |
Bioavailability studies of etofibrate in rhesus monkeys.
Topics: Animals; Biological Availability; Clofibrate; Clofibric Acid; Drug Interactions; Female; Half-Life; Hypolipidemic Agents; Intestinal Absorption; Macaca mulatta; Niacin; Time Factors | 1985 |
Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.
Topics: Aged; Clofibrate; Clofibric Acid; Humans; Hypolipidemic Agents; Kearns-Sayre Syndrome; Male; Microscopy, Electron; Mitochondria, Muscle; Muscles; Muscular Diseases | 1985 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransferase; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Long-Term Care; Male; Middle Aged; Triglycerides; Uric Acid | 1980 |
[Pharmacologic therapy of arteriosclerosis: current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clofibrate; Clofibric Acid; Humans | 1984 |
Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
Topics: Adult; Biological Availability; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hypolipidemic Agents; Kinetics; Male | 1984 |
[Atherosclerosis treatment with etofibrate retard. New perspectives].
Topics: Arteriosclerosis; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Hemodynamics; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Triglycerides; Uric Acid | 1983 |
Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation products.
Topics: Animals; Blood Proteins; Chromatography, High Pressure Liquid; Clofibrate; Clofibric Acid; Dogs; Erythrocytes; Humans; Hydrolysis; In Vitro Techniques; Plasma; Protein Binding; Ultrafiltration | 1983 |
[Longterm therapy and etofibrate (author's transl)].
Topics: Anticholesteremic Agents; Blood Cell Count; Blood Glucose; Clofibrate; Clofibric Acid; Drug Administration Schedule; Drug Tolerance; Humans; Hyperlipoproteinemias; Triglycerides | 1980 |
[Bezafibrate and delayed action etofibrate in hyperlipidemia].
Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Triglycerides | 1983 |
Effects of etofibrate on platelet function: in vitro studies in human plasma.
Topics: Animals; Blood Platelets; Clofibrate; Clofibric Acid; Epoprostenol; Humans; Male; Malondialdehyde; Nicotinic Acids; Platelet Factor 3; Rats; Serotonin | 1980 |
Predictions of stability in pharmaceutical preparations XIX: Stability evaluation and bioanalysis of clofibric acid esters by high-pressure liquid chromatography.
Topics: Animals; Buffers; Chromatography, High Pressure Liquid; Clofibrate; Clofibric Acid; Dogs; Drug Stability; Humans; Hydrogen-Ion Concentration; Hydrolysis; In Vitro Techniques; Kinetics; Models, Chemical | 1982 |
[Lowering lipids rapidly and permanently with etofibrate].
Topics: Cholestyramine Resin; Clofibrate; Clofibric Acid; Dextrothyroxine; Humans; Hyperlipoproteinemias; Lipoproteins, HDL; Liver; Nicotinic Acids; Sitosterols | 1982 |
[Lipid lowering improved? Therapeutic progress by using biological mechanisms].
Topics: Anticholesteremic Agents; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II | 1982 |
[What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
Topics: Anticholesteremic Agents; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipoproteinemias | 1982 |
[Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
Topics: Biotransformation; Clofibrate; Clofibric Acid; Digestive System; Drug Stability; Esterases; Humans; Hydrolases; Hypolipidemic Agents; Kinetics | 1980 |
[Etofibrate lowers the atherosclerosis index].
Topics: Arteriosclerosis; Clofibrate; Clofibric Acid; Humans; Lipids | 1981 |
[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
Topics: Adult; Aged; Bile; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides | 1980 |
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged | 1980 |